MTOR inhibitor therapy for patients with carcinoid

The Lancet

Volumn 378, Issue 9808, 2011, Pages 1978-1980

  Rindi, Guido ^a   Caplin, Martyn ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; EVEROLIMUS; OCTREOTIDE; PLACEBO;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOID SYNDROME; DIARRHEA; DRUG EFFICACY; HUMAN; INFECTION; NEUROENDOCRINE TUMOR; NOTE; OVERALL SURVIVAL; PANCREAS TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TUMOR LOCALIZATION;

EID: 83255193884     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61789-3     Document Type: Note

References (11)

1. M Pavel, JD Hainsworth, E Baudin et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 2011 10.1016/s0140-6736(11)61742-X published online Nov 25.
2. S Oberndorfer Karzinoide tumoren des dünndarms Frankf Z Pathol 1 1907 425 432
3. JC Yao, M Hassan, A Phan et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States J Clin Oncol 26 2008 3063 3072
4. G Rindi, B Wiedenmann Neuroendocrine neoplasms of the gut and pancreas: new insights Nat Rev Endocrinol 2011 10.1038/nrendo.2011.120 published online Aug 2.
5. SB Edge, DR Byrd, CC Compton, AG Fritz, FL Greene, A Trotti AJCC cancer staging manual 2010 Springer New York, NY
6. F Bosman, F Carneiro World Health Organization classification of tumours, pathology and genetics of tumours of the digestive system 2010 IARC Press Lyon
7. G Rindi, R Arnold, C Capella et al. Nomenclature and classification of digestive neuroendocrine tumours F Bosman F Carneiro World Health Organization classification of tumours, pathology and genetics of tumours of the digestive system 2010 IARC Press Lyon 10 12
8. ME Caplin, JR Buscombe, AJ Hilson, AL Jones, AF Watkinson, AK Burroughs Carcinoid tumour Lancet 352 1998 799 805
9. JK Ramage, A Ahmed, J Ardill et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) Gut 2011 10.1136/gutjnl-2011-300831 published online Nov 3.
10. A Rinke, HH Muller, C Schade-Brittinger et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
11. JC Yao, MH Shah, I Tetsuhide et al. Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523